From the *Children's Cancer Centre, The Royal Children's Hospital Melbourne, Parkville; †Department of Infectious Diseases and Infection Control, Peter MacCallum Cancer Centre, East Melbourne, Australia; ‡Department of Pediatrics, Pediatric Oncology Institute (IOP-GRAACC), Federal University of Sao Paulo, São Paulo, Brazil; §Centre for Reviews and Dissemination, Alcuin College, University of York, York; and ¶Regional Department of Paediatric Haematology/Oncology, Leeds Teaching Hospitals Trust, Leeds, United Kingdom.
Pediatr Infect Dis J. 2013 Oct;32(10):e390-6. doi: 10.1097/INF.0b013e31829ae38d.
Fever during neutropenia (FN) is a frequent and potentially life-threatening complication of the treatment of childhood cancer. The role of biomarkers in predicting morbidity and mortality associated with FN in children has been explored with varying results. This systematic review identified, critically appraised and synthesized information on the use of biomarkers for the prediction of outcome of FN in children/young adults, updating a review of initial assessment and adding further analysis of their value at reassessment.
This review was conducted in accordance with the Centre for Reviews and Dissemination Methods, using 3 different random effects meta-analysis models.
Thirty-seven studies involving over 4689 episodes of FN in children were assessed, including an additional 13 studies investigating 18 biomarkers in 1670 FN episodes since the original review. Meta-analysis was possible for admission C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 and interleukin-8 in their ability to detect significant infection. Marked heterogeneity exists, precluding clear clinical interpretation of the results. Qualitative synthesis of the role of serial biomarkers suggests their predictive ability may be more pronounced at 24 to 48 hours compared with admission. Direct comparisons of the discriminatory power of admission values of PCT and CRP showed PCT generally had a better discriminatory estimate of serious infection than CRP.
There remains a paucity of robust and reproducible data on the use of biomarkers in prediction of serious infection in children with FN. Available evidence suggests PCT has better discriminatory ability than CRP and that the role of serial biomarkers warrants further study.
中性粒细胞减少症(FN)期间发热是儿童癌症治疗中常见且潜在威胁生命的并发症。已经探索了生物标志物在预测 FN 相关发病率和死亡率中的作用,但结果不一。本系统评价确定、批判性评价并综合了生物标志物在预测儿童/年轻成人 FN 结局中的应用信息,更新了对初始评估的综述,并进一步分析了它们在重新评估时的价值。
本综述按照中心的审查和传播方法进行,使用了 3 种不同的随机效应荟萃分析模型。
评估了 37 项涉及超过 4689 例儿童 FN 的研究,其中包括自原始综述以来,另外 13 项研究调查了 1670 例 FN 中 18 种生物标志物。荟萃分析可用于入院时 C 反应蛋白(CRP)、降钙素原(PCT)、白细胞介素-6 和白细胞介素-8 检测显著感染的能力。存在明显的异质性,使结果无法进行明确的临床解释。对连续生物标志物作用的定性综合表明,与入院时相比,它们在 24 至 48 小时的预测能力可能更为明显。PCT 和 CRP 入院值的鉴别能力的直接比较表明,PCT 通常比 CRP 更能准确鉴别严重感染。
在预测 FN 儿童严重感染方面,生物标志物的使用仍缺乏稳健且可重复的数据。现有证据表明,PCT 比 CRP 具有更好的鉴别能力,而连续生物标志物的作用值得进一步研究。